The phase III ADAURA study randomized 682 radically operated NSCLC patients with stage IB-IIIA (VII edition of TNM staging) and classic EGFR activating mutations (exon 19 deletion or L588R exon 21 mutations) to receive either osimertinib 80 mg once daily (a third-generation EGFR TKI) or placebo for 3 years. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.